Roivant (ROIV) Director Melissa Epperly Sells Shares

What Happened

• Melissa B. Epperly, a director of Roivant Sciences Ltd. (ROIV), reported sales of a total of 4,938 common shares on September 15, 2026. The reported transactions are: 4,338 shares at a weighted average price of $39.65 (reported value $172,002) and 600 shares at a weighted average price of $40.38 (reported value $24,228). These were sales (not purchases).

Key Details

• Transaction dates: September 15, 2026 (filed on Sep 17, 2026; filing appears timely under Form 4 rules).
• Reported trades:
  • 4,338 shares sold — weighted avg price $39.65; reported total $172,002. Price range for these sales: $39.25–$40.15 (footnote).
  • 600 shares sold — weighted avg price $40.38; reported total $24,228. Price range for these sales: $40.25–$40.50 (footnote).
• Total reported proceeds: approximately $196,230.
• These sales were effected pursuant to a Rule 10b5-1 trading plan adopted March 30, 2026; the filing notes the prices are weighted averages and that the reporting person will provide a breakdown of exact per-share prices upon request.
• Shares owned after the transactions: not specified in the details provided.

Context

• Sales under a Rule 10b5-1 plan are pre-arranged and often used to systematically sell shares; they are common and do not by themselves indicate the director’s current view of the company’s prospects.
• This was an outright sale (transaction code S), not an option exercise, gift, or award.